The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process causing T1D. This approval is based on the phase 3 PROTECT study showing significant preservation of beta-cell function compared to placebo. The drug offers a new treatment option at a stage when symptoms typically appear and insulin therapy becomes necessary. Further confirmatory studies are ongoing to verify clinical benefits.
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
Recludix Pharma announced preclinical results for REX-8756, an oral STAT6 inhibitor, showing strong efficacy and safety in models of allergic asthma and dermatitis. The data, presented at two major allergy and dermatology congresses, indicate that RE...
Sanofi has stopped its Phase 3 MOBILIZE trial testing riliprubart for chronic inflammatory demyelinating polyneuropathy (CIDP) due to unlikely efficacy success, though no safety issues were found. The company will review other riliprubart studies and...
Sanofi has stopped the phase 3 MOBILIZE clinical trial of riliprubart for treating chronic inflammatory demyelinating polyneuropathy (CIDP) after an interim review showed the study is unlikely to demonstrate sufficient efficacy. No safety concerns we...
